It has been shown that oral administration of the selective ROCK2 inhibitor KD025 to healthy subjects or rheumatoid arthritis patients attenuates the ability of T cells to secrete IL-17 in response to stimulation ex vivo via a STAT3-dependent mechanism. Here, IL17A is linked to rheumatoid arthritis.